STELLAR-Rosuvastatin vs. Atorvastatin, Pravastatin, Simvastatin across dose ranges - STELLAR

Study identifier:4522IL/0065

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 6 week Open Label, Dose Comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin versus Atorvastatin, Pravastatin, and Simvastatin in subjects with Hypercholesterolemia.

Medical condition

Hypercholesterolemia

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin, Atorvastatin, Pravastatin, Simvastatin

Sex

All

Actual Enrollment

5625

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Apr 2001

Primary Completion Date: -

Study Completion Date: 01 Oct 2004

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Rosuvastatin	-
Active Comparator: 2 Atorvastatin	-
Active Comparator: 3 Pravastatin	-
Active Comparator: 4 Simvastatin	-

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1565&filename=CSR-4522IL-0065.pdf
Download
CSR-4522IL-0065.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Eleanor Miller

AstraZeneca